Associations Among Nitric Oxide and Enkephalinases With Fibromyalgia Symptoms.
Journal
Nursing research
ISSN: 1538-9847
Titre abrégé: Nurs Res
Pays: United States
ID NLM: 0376404
Informations de publication
Date de publication:
Historique:
entrez:
25
2
2021
pubmed:
26
2
2021
medline:
25
3
2021
Statut:
ppublish
Résumé
Fibromyalgia (FM) is a complex syndrome of uncertain etiology, characterized by the presence of widespread pain. Both nitric oxide and enkephalinases modulate pain perception. The aim of this study was to evaluate the relationships among serum nitric oxide levels, oxytocinase activity, and enkephalin-degrading aminopeptidase (EDA) activity with pain-related clinical manifestations in women with FM. We performed an observational case study in a population of 58 women diagnosed with FM. Serum nitric oxide levels were analyzed by an ozone chemiluminescence-based assay. Both serum oxytocinase and EDA activities were fluorometrically determined. Pain threshold and pain magnitude were evaluated using the PainMatcher. The pressure pain thresholds were measured using a digital pressure algometer. We used a visual analog scale, the Central Sensitization Inventory, the Revised Fibromyalgia Impact Questionnaire, and the Beck Anxiety Inventory to assess the global level of pain, the symptoms associated with the central sensitization syndrome, the severity of FM, and the anxiety level, respectively. Multiple linear regression analysis adjusted by age, body mass index, and menopause status revealed significant associations between nitric oxide levels and dominant occiput pressure pain thresholds, nondominant occiput pressure pain thresholds, and FM effects. Significant associations of oxytocinase activity with the visual analog scale and dominant knee pressure pain thresholds were also found. Moreover, results showed a significant association between high EDA activity levels and dominant second-rib pressure pain thresholds. Our data have shown significant relationships of serum nitric oxide levels and oxytocinase and EDA activities with some body pressure pain thresholds, the daily activity level, and the global intensity of pain in women with FM. These results suggest that pain, which is the main symptom of this syndrome, may be related to alterations in nitric oxide levels and in oxytocinase and EDA activities in patients with FM.
Sections du résumé
BACKGROUND
Fibromyalgia (FM) is a complex syndrome of uncertain etiology, characterized by the presence of widespread pain. Both nitric oxide and enkephalinases modulate pain perception.
OBJECTIVES
The aim of this study was to evaluate the relationships among serum nitric oxide levels, oxytocinase activity, and enkephalin-degrading aminopeptidase (EDA) activity with pain-related clinical manifestations in women with FM.
METHODS
We performed an observational case study in a population of 58 women diagnosed with FM. Serum nitric oxide levels were analyzed by an ozone chemiluminescence-based assay. Both serum oxytocinase and EDA activities were fluorometrically determined. Pain threshold and pain magnitude were evaluated using the PainMatcher. The pressure pain thresholds were measured using a digital pressure algometer. We used a visual analog scale, the Central Sensitization Inventory, the Revised Fibromyalgia Impact Questionnaire, and the Beck Anxiety Inventory to assess the global level of pain, the symptoms associated with the central sensitization syndrome, the severity of FM, and the anxiety level, respectively.
RESULTS
Multiple linear regression analysis adjusted by age, body mass index, and menopause status revealed significant associations between nitric oxide levels and dominant occiput pressure pain thresholds, nondominant occiput pressure pain thresholds, and FM effects. Significant associations of oxytocinase activity with the visual analog scale and dominant knee pressure pain thresholds were also found. Moreover, results showed a significant association between high EDA activity levels and dominant second-rib pressure pain thresholds.
DISCUSSION
Our data have shown significant relationships of serum nitric oxide levels and oxytocinase and EDA activities with some body pressure pain thresholds, the daily activity level, and the global intensity of pain in women with FM. These results suggest that pain, which is the main symptom of this syndrome, may be related to alterations in nitric oxide levels and in oxytocinase and EDA activities in patients with FM.
Identifiants
pubmed: 33630539
doi: 10.1097/NNR.0000000000000496
pii: 00006199-202103000-00012
doi:
Substances chimiques
Nitric Oxide
31C4KY9ESH
Aminopeptidases
EC 3.4.11.-
enkephalin degrading enzyme
EC 3.4.11.14
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E11-E20Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Alstergren P., Förström J. (2003). Acute oral pain intensity and pain threshold assessed by intensity matching to pain induced by electrical stimuli. Journal of Orofacial Pain, 17, 151–159.
Arout C. A., Sofuoglu M., Bastian L. A., Rosenheck R. A. (2018). Gender differences in the prevalence of fibromyalgia and in concomitant medical and psychiatric disorders: A national Veterans Health Administration study. Journal of Women's Health, 27, 1035–1044 https://doi.org/10.1089/jwh.2017.6622
doi: 10.1089/jwh.2017.6622
Bellato E., Marini E., Castoldi F., Barbasetti N., Mattei L., Bonasia D. E., Blonna D. (2012). Fibromyalgia syndrome: Etiology, pathogenesis, diagnosis, and treatment. Pain Research and Treatment, 2012, 426130 https://doi.org/10.1155/2012/426130
doi: 10.1155/2012/426130
Bradford M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248–254 https://doi.org/10.1006/abio.1976.9999
doi: 10.1006/abio.1976.9999
Braman R. S., Hendrix S. A. (1989). Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium(III) reduction with chemiluminescence detection. Analytical Chemistry, 61, 2715–2718 https://doi.org/10.1021/ac00199a007
doi: 10.1021/ac00199a007
Buskila D., Neumann L., Alhoashle A., Abu-Shakra M. (2000). Fibromyalgia syndrome in men. Seminars in Arthritis and Rheumatism, 30, 47–51 https://doi.org/10.1053/sarh.2000.8363
doi: 10.1053/sarh.2000.8363
Cabo-Meseguer A., Cerdá-Olmedo G., Trillo-Mata J. L. (2017). Fibromyalgia: Prevalence, epidemiologic profiles and economic costs. Medicina Clinica, 149, 441–448 https://doi.org/10.1016/j.medcli.2017.06.008
doi: 10.1016/j.medcli.2017.06.008
Çakit M. O., Çakit B. D., Genç H., Pervane Vural S., Erdem H. R., Saraçoğlu M., Karagöz A. (2018). The association of skinfold anthropometric measures, body composition and disease severity in obese and non-obese fibromyalgia patients: A cross-sectional study. Archives of Rheumatology, 33, 59–65 https://doi.org/10.5606/ArchRheumatol.2018.6180
doi: 10.5606/ArchRheumatol.2018.6180
Carrera M. P., Ramírez-Expósito M. J., Valenzuela M. T., García M. J., Mayas M. D., Martínez-Martos J. M. (2004). Serum oxytocinase activity is related to tumor growth parameters in N-methyl nitrosourea induced rat breast cancer. Life Sciences, 75, 1369–1377 https://doi.org/10.1016/j.lfs.2004.04.009
doi: 10.1016/j.lfs.2004.04.009
Chesterton L. S., Sim J., Wright C. C., Foster N. E. (2007). Interrater reliability of algometry in measuring pressure pain thresholds in healthy humans using multiple raters. The Clinical Journal of Pain, 23, 760–766 https://doi.org/10.1097/AJP.0b013e318154b6ae
doi: 10.1097/AJP.0b013e318154b6ae
Chinn S., Caldwell W., Gritsenko K. (2016). Fibromyalgia pathogenesis and treatment options update. Current Pain and Headache Reports, 20, 25 https://doi.org/10.1007/s11916-016-0556-x
doi: 10.1007/s11916-016-0556-x
Çimen Ö. B., Çimen M. Y. B., Yapici Y., Çamdeviren H. (2009). Arginase, NOS activities, and clinical features in fibromyalgia patients. Pain Medicine, 10, 813–818 https://doi.org/10.1111/j.1526-4637.2009.00642.x
doi: 10.1111/j.1526-4637.2009.00642.x
Coskun Benlidayi I. (2019). Role of inflammation in the pathogenesis and treatment of fibromyalgia. Rheumatology International, 39, 781–791. https://doi.org/10.1007/s00296-019-04251-6.
doi: 10.1007/s00296-019-04251-6
Cuesta-Vargas A. I., Roldan-Jimenez C., Neblett R., Gatchel R. J. (2016). Cross-cultural adaptation and validity of the Spanish central sensitization inventory. Springerplus, 5, 1837 https://doi.org/10.1186/s40064-016-3515-4
doi: 10.1186/s40064-016-3515-4
Cury Y., Picolo G., Gutierrez V. P., Ferreira S. H. (2011). Pain and analgesia: The dual effect of nitric oxide in the nociceptive system. Nitric Oxide - Biology and Chemistry, 25, 243–254 https://doi.org/10.1016/j.niox.2011.06.004
doi: 10.1016/j.niox.2011.06.004
Fernández-Lao C., Galiano-Castillo N., Cantarero-Villanueva I., Martín-Martín L., Prados-Olleta N., Arroyo-Morales M. (2016). Analysis of pressure pain hypersensitivity, ultrasound image, and quality of life in patients with chronic plantar pain: A preliminary study. Pain Medicine (United States), 17, 1530–1541 https://doi.org/10.1093/pm/pnv022
doi: 10.1093/pm/pnv022
García-López M. J., Martínez-Martos J. M., Mayas M. D., Carrera M. P., Ramírez-Expósito M. J. (2003). Effects of orchidectomy and testosterone replacement on mouse enkephalin-degrading aminopeptidase activity in the HPA axis. General and Comparative Endocrinology, 134, 303–307 https://doi.org/10.1016/s0016-6480(03)00270-3.
doi: 10.1016/s0016-6480
Gratt B. M., Anbar M. (2005). A pilot study of nitric oxide blood levels in patients with chronic orofacial pain. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, 100, 441–448 https://doi.org/10.1016/j.tripleo.2004.02.081
doi: 10.1016/j.tripleo.2004.02.081
Gulati K., Rai N., Ray A. (2017). Nitric oxide and anxiety. Vitamins and Hormones, 103, 169–192 https://doi.org/10.1016/bs.vh.2016.09.001
doi: 10.1016/bs.vh.2016.09.001
Henry M. S., Gendron L., Tremblay M. E., Drolet G. (2017). Enkephalins: Endogenous analgesics with an emerging role in stress resilience. Neural Plasticity, 2017, 1546125 https://doi.org/10.1155/2017/1546125
doi: 10.1155/2017/1546125
Jones D. H., Kilgour R. D., Comtois A. S. (2007). Test-retest reliability of pressure pain threshold measurements of the upper limb and torso in young healthy women. Journal of Pain, 8, 650–656 https://doi.org/10.1016/j.jpain.2007.04.003
doi: 10.1016/j.jpain.2007.04.003
Kanabrocki E. L., George M., Hermida R. C., Messmore H. L., Ryan M. D., Ayala D. E., Hoppensteadt D. A., Fareed J., Bremner F. W., Third J. L., Shirazi P., Nemchausky B. A. (2001). Day-night variations in blood levels of nitric oxide, T-TFPI, and E-selectin. Clinical and Applied Thrombosis/Hemostasis, 7, 339–345 https://doi.org/10.1177/107602960100700417
doi: 10.1177/107602960100700417
Koca T. T., Seyithanoglu M., Sagiroglu S., Berk E., Dagli H. (2018). Frequency of audiological complaints in patients with fibromyalgia syndrome and its relationship with oxidative stress. Nigerian Journal of Clinical Practice, 21, 1271–1277 https://doi.org/10.4103/njcp.njcp_95_18
doi: 10.4103/njcp.njcp_95_18
La Rubia M., Rus A., Molina F., Del Moral M. L. (2013). Is fibromyalgia-related oxidative stress implicated in the decline of physical and mental health status?Clinical and Experimental Rheumatology, 31, S121–S127.
Lund I., Lundeberg T., Kowalski J., Sandberg L., Budh C. N., Svensson E. (2005). Evaluation of variations in sensory and pain threshold assessments by electrocutaneous stimulation. Physiotherapy Theory and Practice, 21, 81–92 https://doi.org/10.1080/09593980590922307
doi: 10.1080/09593980590922307
Magán I., Sanz J., García-Vera M. P. (2008). Psychometric properties of a Spanish version of the Beck Anxiety Inventory (BAI) in general population. The Spanish Journal of Psychology, 11, 626–640.
Marques A. P., Assumpção A., Matsutani L. A., Bragança Pereira C. A., Lage L. (2008). Pain in fibromyalgia and discrimination power of the instruments: Visual Analog Scale, Dolorimetry and the McGill Pain Questionnaire. Acta Reumatologica Portuguesa, 33, 345–351.
Martínez-Martos J. M., Correa-Rodríguez M., Rus A., Molina F., Ramírez-Expósito M. J., Aguilar-Ferrandiz M. E. (2019). Altered serum oxytocinase and enkephalin-degrading aminopeptidase activities in patients with fibromyalgia. Biological Research for Nursing, 21, 431–439 https://doi.org/10.1177/1099800419854207
doi: 10.1177/1099800419854207
Mas A. J., Carmona L., Valverde M., Ribas B., Aretxabala I., Ballina J., Beltrán J., Benito P., Benito S., Calabozo M., Cobeta J. C., Corral C., Ciria M., Fernández-Carballido C., Fernández J. A., Fernández-Sueiro J. L., Gabriel R., Garrido G., Grandal Y., Yelin E. (2008). Prevalence and impact of fibromyalgia on function and quality of life in individuals from the general population: Results from a nationwide study in Spain. Clinical and Experimental Rheumatology, 26, 519–526.
Neblett R., Cohen H., Choi Y., Hartzell M. M., Williams M., Mayer T. G., Gatchel R. J. (2013). The central sensitization inventory (CSI): Establishing clinically significant values for identifying central sensitivity syndromes in an outpatient chronic pain sample. Journal of Pain, 14, 438–445 https://doi.org/10.1016/j.jpain.2012.11.012
doi: 10.1016/j.jpain.2012.11.012
Neblett R., Hartzell M. M., Mayer T. G., Cohen H., Gatchel R. J. (2017). Establishing clinically relevant severity levels for the Central Sensitization Inventory. Pain Practice, 17, 166–175 https://doi.org/10.1111/papr.12440
doi: 10.1111/papr.12440
Neumann D. I., Slattery D. A. (2016). Oxytocin in general anxiety and social fear: A translational approach. Biological Psychiatry, 79, 213–221 https://doi.org/10.1016/j.biopsych.2015.06.004
doi: 10.1016/j.biopsych.2015.06.004
Nijs J., Loggia M. L., Polli A., Moens M., Huysmans E., Goudman L., Meeus M., Vanderweeën L., Ickmans K., Clauw D. (2017). Sleep disturbances and severe stress as glial activators: Key targets for treating central sensitization in chronic pain patients?Expert Opinion on Therapeutic Targets, 21, 817–826 https://doi.org/10.1080/14728222.2017.1353603
doi: 10.1080/14728222.2017.1353603
Ozgocmen S., Ozyurt H., Sogut S., Akyol O., Ardicoglu O., Yildizhan H. (2006). Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: Etiologic and therapeutic concerns. Rheumatology International, 26, 598–603 https://doi.org/10.1007/s00296-005-0079-y
doi: 10.1007/s00296-005-0079-y
Rus A., Castro L., Del Moral M. L., Peinado Á. (2010). Inducible NOS inhibitor 1400W reduces hypoxia/re-oxygenation injury in rat lung. Redox Report, 15, 169–178 https://doi.org/10.1179/174329210X12650506623609
doi: 10.1179/174329210X12650506623609
Rus A., Molina F., Gassó M., Camacho M. V., Peinado M. Á., del Moral M. L. (2016). Nitric oxide, inflammation, lipid profile, and cortisol in normal- and overweight women with fibromyalgia. Biological Research for Nursing, 18, 138–146 https://doi.org/10.1177/1099800415591035
doi: 10.1177/1099800415591035
Russell I. J., Larson A. A. (2009). Neurophysiopathogenesis of fibromyalgia syndrome: A unified hypothesis. Rheumatic Disease Clinics of North America, 35, 421–435 https://doi.org/10.1016/j.rdc.2009.06.005
doi: 10.1016/j.rdc.2009.06.005
Salgueiro M., García-Leiva J. M., Ballesteros J., Hidalgo J., Molina R., Calandre E. P. (2013). Validation of a Spanish version of the Revised Fibromyalgia Impact Questionnaire (FIQR). Health and Quality of Life Outcomes, 11, 132 https://doi.org/10.1186/1477-7525-11-132
doi: 10.1186/1477-7525-11-132
Sanz J., Navarro M. E. (2003). The psychometric properties of a Spanish version of the Beck Anxiety Inventory (BAI) in a university students sample. Ansiedad y Estrés, 9, 59–84.
Sarzi-Puttini P., Giorgi V., Marotto D., Atzeni F. (2020). Fibromyalgia: An update on clinical characteristics, aetiopathogenesis and treatment. Nature Reviews. Rheumatology, 16, 645–660 https://doi.org/10.1038/s41584-020-00506-w
doi: 10.1038/s41584-020-00506-w
Sendur O. F., Turan Y., Tastaban E., Yenisey C., Serter M. (2009). Serum antioxidants and nitric oxide levels in fibromyalgia: A controlled study. Rheumatology International, 29, 629–633 https://doi.org/10.1007/s00296-008-0738-x
doi: 10.1007/s00296-008-0738-x
Sluka K. A., Clauw D. J. (2016). Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience, 338, 114–129 https://doi.org/10.1016/j.neuroscience.2016.06.006
doi: 10.1016/j.neuroscience.2016.06.006
Stisi S., Cazzola M., Buskila D., Spath M., Giamberardino M. A., Sarzi-Puttini P., Arioli G., Alciati A., Leardini G., Gorla R., Marsico A., Ceccherelli F., Bazzichi L., Carignola R., Gracely R. H., Salaffi F., Marinangeli F., Torta R., Di Franco M., Atzeni F. (2008). Etiopathogenetic mechanisms of fibromyalgia syndrome. Reumatismo, 60, 25–35.
Sturgeon J. A., Darnall B. D., Zwickey H. L., Wood L. J., Hanes D. A., Zava D. T., Mackey S. C. (2014). Proinflammatory cytokines and DHEA-S in women with fibromyalgia: Impact of psychological distress and menopausal status. Journal of Pain Research, 7, 707–716 https://doi.org/10.2147/JPR.S71344
doi: 10.2147/JPR.S71344
Watt E. F. (2018). Musculoskeletal pain and menopause. Post Reproductive Health, 24, 34–43 https://doi.org/10.1177/2053369118757537
doi: 10.1177/2053369118757537
Wolfe F., Clauw D. J., Fitzcharles M. A., Goldenberg D. L., Katz R. S., Mease P., Russell A. S., Russell I. J., Winfield J. B., Yunus M. B. (2010). The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research, 62, 600–610 https://doi.org/10.1002/acr.20140
doi: 10.1002/acr.20140
Xin Q., Bai B., Liu W. (2017). The analgesic effects of oxytocin in the peripheral and central nervous system. Neurochemistry International, 103, 57–64 https://doi.org/10.1016/j.neuint.2016.12.021
doi: 10.1016/j.neuint.2016.12.021